ObjectiveTo investigate the change of subfoveal choroidal thickness (SFCT) and the relationship between SFCT and the severity of the diabetic retinopathy using enhanced depth imaging optical coherence tomography (EDI-OCT). MethodsA total of 164 eyes (93 patients) of type 2 diabetes mellitus (DM) were included in this study. The patients included 34 males and 59 females, with an average age of (59.3±5.6) years, with an average diabetes duration of (5.11±4.64) years. The patients were divided into 4 groups according to international classification standards of DR, including non-diabetic retinopathy (NDR) group (64 eyes), mild non-proliferative diabetic retinopathy (NPDR) group (33 eyes), moderate NPDR group (37 eyes), and severe NPDR group (30 eyes). The control group included 25 normal subjects (42 eyes). All patients underwent visual acuity, intraocular pressure, slit lamp microscope, indirect ophthalmoscope, A/B-type ultrasound scan, frequency domain optical coherence tomography (SD-OCT) examination, as well as fasting blood glucose and mean arterial blood pressure measurement. The mean axial length was (23.04±0.78) mm, mean fasting blood glucose was (8.88±2.59) mmol/L, mean arterial pressure was (100.44±9.63) mmHg. SFCT of all eyes were measured by EDI-OCT. The relationship between SFCT and the severity of the diabetic retinopathy, DM duration, fasting blood glucose, the mean arterial pressure, axial length was analyzed by one-way ANOVA. ResultsThe mean SFCT was (224.24±42.10) μm in DM group and (276.77±48.07) μm in normal control group, the difference was statistically significant (F=23.86, P < 0.05). The mean SFCT was also statistically significant between all DM groups (P < 0.05). There were negative linear correlation between SFCT of all patients and the severity of retinal lesions (r=-0.555, P=0.000), and between SFCT and DM duration (r=-0.332, P < 0.05). But SFCT was independent of fasting plasma glucose (r=-0.123, P > 0.05), mean arterial pressure (r=-0.116, P > 0.05), and axial length (r=-0.018, P > 0.05). ConclusionsSFCT in DM eyes is thinner than that in normal controls. SFCT is different in the NDR, mild NPDR, moderate NPDR, severe NPDR patient. Severe DR patients have much thinner SFCT.
Objective To analyze the clinical efficacy and safety of endostar or carboplatin combined with endostar intracavitary perfusion in the treatment of malignant serous cavity effusion. Methods We retrospectively reviewed the clinical data of 78 cancer patients with malignant serous cavity effusion who received paracentesis and intracavitary endostar, or carboplatin combined with endostar in Shengjing Hospital of China Medical University between November 2011 and November 2016. There were 42 males and 36 females at a median age of 62 years ranging from 17 to 78 years. According to treatment methods, 78 patients were divided into two groups, in which 33 patients received intracavitary endostar combined with carboplatin (a combination group, 15 males and 18 females at a median age of 56 years ranging from 17 to 66 years), and 45 patients received intracavitary endostar (an endostar group, 27 males and 18 females at a median age of 63 years ranging from 38 to 78 years). The efficacy and safety of two methods were analyzed and compared. Results The response rate in the combination group was 75.8%, which was higher than that in the endostar group (60.0%, P=0.035). In quality of life improvement, there was no statistical difference between the two groups (P=0.113). The incidence of fatigue, myelosuppression and gastrointestinal reactions in the endostar group was significantly lower than that of the combination group (P=0.006, 0.000 and 0.017, respectively). Analysis of long-term efficacy revealed that the median time to progress (TTP) in the combination group and endostar group was 171 days and 143 days, respectively (P=0.030). Conclusion Intracavitary infusion of endostar alone, or carboplatin combined with endostar is effective and tolerable for controlling malignant serous cavity effusion. But for the patients with poor physical state who can not tolerant platinum perfusion, intracavitary infusion of endostar alone can be adopted to control malignant serous cavity effusion.